Peter C Brooks

This inventor holds 34 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Angiogenesis Inhibition. Top assignees: New York University, Scripps Research Institute, University of Southern California. Active years: 1998-2024.

USPTO Granted Patents = 34 (Patent Applications = 7)

% Patents Active = 41.2

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 245(Granted Patents)

Location History:

San Diego, CA (US) (1998)
West Harrison, NY (US) (2005 - 2009)
Los Angeles, CA (US) (2009)
Hollywood, CA (US) (2002 - 2011)
Carmel, NY (US) (2008 - 2012)
Scarborough, ME (US) (2012)
Harpswell, ME (US) (2014 - 2024)

Company Filing History:

Scripps Research Institute

patents

7 out of 1,690

University of Southern California

Maine Medical Center Research Institute

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

Areas of Expertise:

Immune Checkpoint Inhibitor

Angiogenesis

Cancer Treatment

Collagen Antibodies

Benzoic Acid Derivatives

Neovascular Glaucoma

Fibrosis

Melanoma Metastasis

PABA

MMP-9

Alphavbeta3 Antibodies

STQ Peptides

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11998600 - Enhancing the therapeutic activity of an immune checkpoint inhibitor (2024-06-04),

2. 10906977 - Enhancing the therapeutic activity of immune checkpoint inhibitor (2021-02-02),

3. 10881732 - Enhancing the therapeutic activity of an immune checkpoint inhibitor (2021-01-05),

4. 9890208 - Compositions and methods for treating inflammation and fibrosis (2018-02-13),

5. 9018259 - Treatment of cancer using benzoic acid derivatives (2015-04-28),

6. 8710099 - Treatment of cancer using the sodium salt of a benzoic acid derivative (2014-04-29),

7. 8198328 - Treatment of cancer using benzoic acid derivatives (2012-06-12),

8. 8133471 - CLK-peptide and SLK-peptide (2012-03-13),

9. 8025883 - Antagonists and methods for inhibiting angiogenesis (2011-09-27),

10. 7763248 - Humanized collagen antibodies and related methods (2010-07-27),

11. 7763247 - Humanized collagen antibodies and related methods (2010-07-27),

12. 7705049 - Methods for treating non-melanoma cancers with PABA (2010-04-27),

13. 7691905 - Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) (2010-04-06),

14. 7662783 - CLK-peptide and SLK-peptide (2010-02-16),

15. 7601694 - CLK-peptide and SLK-peptide (2009-10-13),

Title: The Innovative Contributions of Peter C. Brooks

Introduction

Peter C. Brooks, located in Carmel, NY, is a notable inventor with an impressive portfolio of 33 patents. His work primarily focuses on advancements in the field of cancer treatment, showcasing his dedication to improving therapeutic options for patients.

Latest Patents

Among his latest patents is a groundbreaking invention aimed at enhancing the therapeutic activity of immune checkpoint inhibitors. This invention provides antagonists and methods of use that are pivotal in the treatment of cancer and abnormal immune suppression diseases, setting a new standard in oncological therapy. Another patent with similar objectives reiterates the significance of his research in the fight against these serious health challenges.

Career Highlights

Peter has worked with esteemed institutions such as The Scripps Research Institute and New York University, where he has made significant contributions to research and innovation. His expertise has established him as a prominent figure within the scientific community, particularly in cancer immunotherapy.

Collaborations

Throughout his career, Peter has collaborated with notable professionals, including David A. Cheresh and Dorothy Rodriguez. These partnerships have further strengthened his research efforts and expanded the impact of his inventions on the scientific landscape.

Conclusion

Peter C. Brooks is a distinguished inventor whose work has the potential to revolutionize cancer treatment. With a solid foundation of patents and impressive collaborations, he continues to pave the way for innovative solutions in the medical field. His contributions are crucial not only to the advancement of therapeutic techniques but also to the future of cancer research.